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The chronic autoimmune inflammatory diseases, systemic lupus erythematosus and 
Sjogren’s syndrome, develop when tolerance to apoptotic cells (ACs) is lost. We have 
previously reported that this tolerance is maintained by innate-like, IL-10 secreting 
regulatory B cells. Two questions remained. First, do these regulatory B cells belong 
predominantly to a single subset of steady-state B cells and second, what is their spec-
ificity? We report here that innate-like B cells with markers characteristic for B1a cells 
(CD43+veCD19hiCD5+veIgMhiIgDlo) constitute 80% of splenic and 96% of peritoneal B cells 
that respond to ACs by secreting IL-10. AC responsive B1a cells secrete self-reactive 
natural antibodies (NAbs) and IL-10, which is augmented by toll-like receptor (TLR) 7 or 
TLR9 stimulation. In so doing, they both accelerate the clearance of dying cells by mac-
rophages and inhibit their potential to mount proinflammatory immune responses. While 
B1a cells make prolonged contact with ACs, they do not require TIM1 or complement 
to mediate their regulatory function. In an animal model of neural inflammation (exper-
imental autoimmune encephalomyelitis), just 105 activated B1a B  cells was sufficient 
to restrain inflammation. Activated B1a B cells also induced antigen-specific T cells to 
secrete IL-10. Hence, regulatory B1a cells specifically recognize and augment tolerance 
to apoptotic self via IL-10 and NAbs; but once activated, can also prevent autoimmune 
mediated inflammation.
Keywords: regulatory, B cell, B1a, apoptotic cell, immune tolerance
inTrODUcTiOn
Some years ago, Wolf et al. noted that B cell-deficient mice develop a chronic form of neural inflam-
mation called experimental autoimmune encephalomyelitis (EAE) (1), which was later attributed 
to the loss of B cell IL-10 production (2). IL-10 is a broad spectrum anti-inflammatory cytokine 
that potently suppresses the activation of macrophages and dendritic cells (3, 4). Further studies 
have failed to identify a specific subset of IL-10 secreting regulatory B cells that express a particular 
transcription factor, akin to Foxp3 regulatory T  cells (5–7). Instead, B  cells with a capacity to 
regulate immune responses via IL-10 secretion have been described among activated B cells that 
express the surface markers CD5 and CD1d (8, 9), T2-marginal zone precursor B cells (10, 11), and 
plasma cells (12, 13).
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Our own focus has been to understand whether regulatory 
B cells play a role in preventing a breakdown in tolerance to apop-
totic cells (ACs) (7, 14, 15), the loss of which leads to autoimmune 
rheumatic diseases, including systemic lupus erythematosus 
(SLE), Sjogren’s syndrome, and systemic sclerosis (16). Following 
programmed cell death, ACs express immunogenic intracellular 
(IC) self-antigens on their cell surface (17–19). The mechanism 
for maintaining tolerance to apoptotic self is believed to rely 
almost exclusively on their rapid clearance by phagocytes (20, 21), 
which is accelerated by polyreactive natural antibodies (NAbs) 
that bind to AC expressed neoantigens (22). While central and 
peripheral tolerance mechanisms also purge many self-reactive 
B and T cells; a population of innate-like B cells, within the mar-
ginal zone (MZB) and B1a subsets, are selected on their ability to 
respond to self, developing normally even in the absence of for-
eign antigenic stimulation (23, 24). B1a cells are a major source of 
IL-10 (25), inhibiting the progression of both innate and adaptive 
immune responses, preventing tissue damage, but at the cost of 
impeding pathogen clearance (26). The presence of self-reactive 
innate-like B cells is not normally associated with autoimmunity, 
in spite of their frequent exposure to ACs in secondary lymphoid 
organs and sites of inflammation. Conversely, B1a B  cells are 
also known as essential first responders to pathogens in the lung 
and gut, secreting proinflammatory GM-CSF (24, 27–29). Thus, 
a mechanism to ensure that ACs are sensed as tolerogenic by 
innate-like B cells is likely to be important.
We have previously reported, that splenic CD21hiCD23low 
B cells and CD5+ve peritoneal B cells can be activated by antigen-
specific T  cells (via CD40) or directly via toll-like receptor 
(TLR) ligands to secrete IL-10 in response to ACs. In vivo, mice 
given ACs at the time of inducing collagen-induced arthritis or 
EAE are protected from inflammation, generating lower titers 
of auto-antibodies, along with an increase in antigen-specific 
IL-10 secreting T  cells (14). The B  cells sense AC expressed 
DNase-sensitive determinants via their BCR and make IL-10 in a 
TLR9-dependent process (15). However, we do not know which 
particular antigens self-reactive regulatory B  cells recognize or 
whether immune regulatory function is mediated predominantly 
by a particular subset of B cells.
This study addressed those questions and identified that 80% 
of splenic and 96% of peritoneal, AC responsive, innate-like regu-
latory B cells were B1a B cells. AC responsive regulatory B cells 
(ACBregs) make prolonged contact with ACs and secrete both 
IL-10 and self-reactive NAbs. This both enhances AC clearance 
and likely prevents a breach in self-tolerance. Additionally, they 
induce naive T cells to secrete IL-10, but they do not require the 
expression of Tim1 or C1q to exert their regulatory function.
MaTerials anD MeThODs
Mice
IL-10-GFP, TIM1−/− C57BL/6 (see Figure S2Cii in Supplementary 
Material for assessment of genotype), TIM1−/− BALB/c (see Figure 
S2Ci in Supplementary Material for assessment of genotype), 
C1q−/−, complement receptor 2−/− (CR2−/−) (see Figure S2J in 
Supplementary Material for confirmation of phenotype), DO11.10 
TcR Tg mice, and OTII-Ly5.1 TcR Tg mice (both OVA323–339 peptide 
specific) were bred and maintained under specific pathogen free 
conditions in the Animal Facilities at the University of Edinburgh, 
UK. IL-10-GFP mice were kindly provided by Dr. Richard Flavell 
(Yale University, New Haven, CT, USA), TIM1−/− mice by Prof. 
Andrew McKenzie (Cambridge, UK), C1q−/− mice by Prof. 
M. Botto (Imperial) and CR2−/− mice by Prof. Kevin Marchbank 
(Newcastle). Wild-type (WT) C57BL/6 and BALB/c mice were 
bred in house. Mice were used at 8 –12  weeks of age and were 
sex and age matched. All experiments were covered by a Project 
License granted by the Home Office under the Animal (Scientific 
Procedures) Act 1986. Locally, this license was approved by the 
University of Edinburgh Ethical Review Committee.
Flow cytometry and Facs sorting
For all staining, cells were stained in PBS with 2% FCS for 20 min 
at 4°C. BD Aria II was used for flow sorting and BD LSRII was 
used to collect data. For sorted cells, debris and dead cells were 
excluded using FSC-SSC. Doublets were excluded using both 
FSC and SSC singlet gating, then CD19+ve B  cells isolated. For 
Figures 1C and 2A, CD4 and CD3 stains were also included to 
exclude contaminating T  cells. Antibodies used were specific 
for and labeled with CD21-FITC, CD3-PE TxR, CD4-PE, IgM-
APC, GM-CSF-PE, IL-10-PE, IL-17-alexa fluor647, IFN-γ-FITC 
(BD Biosciences); CD11b-BV570, CD11b-PE Cy5, CD19-PE, 
CD19-BV605, CD1d-PerCP Cy5.5, CD21/35-APC, CD23-PE, 
CD23-alexa fluor 647, CD23-PE Cy7, CD3-FITC, CD3 PE/
Dazzle 594, CD38-PE, CD4-PE, CD4-BV605, CD40-PE Cy7, 
CD43-FITC, CD43-APC, CD5-PE Cy5, CD80-PerCP Cy5.5, 
CD86-BV421, TIM1-PE, TNFα-BV605 (Biolegend); CD21/35-
APC efluor780, CD24-APC efluor780, CD25-efluor450, CD9-
APC, DO11.10 TCR-Biotin, IgD-efluor450, MHCII-PE Cy5, 
CD19-eFluor450, F4/80-APC, IFN-γ-PE Cy7, streptavidin-PE 
(eBioscience); IgM-TxR, IgM-alexa fluor647 (Southern Biotech); 
IgM-alexa488, cell tracker green (Molecular Probes), and CFSE 
(fluka). All analysis was performed using FlowJo Software.
ic staining
Cells were stimulated for 4.5 h total with PMA [Sigma (20 ng/ml)] 
and Ionomycin [Sigma (1 μg/ml)]. After 1 h stimulation, Brefeldin 
A [Sigma (1 μg/ml)] was added for the remaining 3.5 h. Surface 
staining was performed before resuspending in fixation and 
permeabilization solution for 20 min (Cytofix/Cytoperm kit, BD 
Biosciences) followed by IC staining. All IC antibodies were used 
at 1:100 for 30 min in 1× Perm/Wash buffer (Cytofix/Cytoperm 
kit, BD Biosciences).
Thymus ac generation
Thymi were removed from 4- to 6-week-old syngeneic mice, 
teased into single cell suspensions and cultured for 18 h in IMDM 
(supplemented with 100 U/ml penicillin, 100 μg/ml streptomy-
cin, 20 mM 2-mercaptoethanol, and 10% heat inactivated FCS). 
Cells prepared in this way give an average of 43% Annexin-V 
(AnV)+ve/propidium iodide (PI)−ve ACs and <5% AnV+ve/PI+ve 
secondary necrotic cells (14). Where ACs are needed for experi-
ments involving C1q−/− ACs were generated following culture in 
X-Vivo 15 media without serum.
FigUre 1 | Continued
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FigUre 1 | IL-10+ve apoptotic cell (AC) responsive B cells express CD43+CD24hiCD21hiCD23loIgDloIgMhi. (a) Splenic CD19+ve cells were FACS sorted (i) into 
CD24loCD21lo (A1; 69.8% of all B cells) and CD24hiCD21hi (A2; 9.8% of all B cells). A2 was further sorted into CD23lo (A3 50.8% of A2) and CD23hi (A4 48.9% of A2). 
B cells from A1, A3, and A4 were activated through TLR7/8 (with R848) (ii) or TLR9 (with CpGB) (iii) with apoptotic cells (solid bars) or without apoptotic cells 
(patterned bars). IL-10 was measured in the supernatants after 72 h. See Figure S1A in Supplementary Material for cell purity. (B) Splenic CD19+ve cells were FACS 
sorted (i) into IgDhiIgMlo (C1 52.5% of all B cells) and IgDloIgMhi (C2 13.1% of all B cells). C2 was further sorted into CD21lo (C3 49.7% of C2) and CD21hi (C4 46.5% 
of C2). C1, C3, and C4 were cultured in the presence of R848 with apoptotic cells. IL-10 (ii) and IL-35 (iii) was measured in the supernatants after 72 h. See Figure 
S1B in Supplementary Material for cell purity. (c) Apoptotic cells were injected IV on D0, 2, and 5 into IL-10-GFP expressing mice. Splenic CD19+ve cells were 
isolated on D7. (i) IL-10+ve B cells. (ii) Surface markers of IL-10-GFP+ve B cells (in red) and IL-10-GFP−ve B cells (in black) compared to isotype control (in shaded 
gray). (iii) The fold difference in mean florescence intensity (MFI) (IL-10-GFP+ve versus IL-10-GFP−ve B cells), is shown for a range of other surface markers. See Figure 
S1C in Supplementary Material for sorting strategy and cell purity. (D) CD19+ve B cells were sorted into MZB (CD19+veCD23loCD21hiCD43−ve), B1a 
(CD19+veCD23loCD21hiCD43+ve) B cells, and follicular B (FOB) cells (CD19+veCD23+veCD21loCD43−ve). Cells were cultured with 2 μg/ml OVA peptide, DO11.10 CD4+ 
T cells ± apoptotic cells. After 72 h cells, the total IL-10 secreted by stimulated B and T cells was measured by ELISA. (e) Apoptotic cells were injected IV on D0, 2, 
and 5 into IL-10-GFP expressing mice. Peritoneal cavity CD19+ve cells were isolated on D7. (i) IL-10+ve B cells. (ii) Surface markers of IL-10-GFP+ve B cells (in red) and 
IL-10-GFP−ve B cells (in black) compared to isotype control (in shaded gray). (iii) The fold difference in MFI (IL-10-GFP+ve versus IL-10-GFP−ve B cells), is shown for a 
range of other surface markers. (F) CD43+ve splenic and peritoneal B1 B cells express higher levels of transcription factor Bhlhe41, when compared to splenic FOB 
and marginal zone B cells or peritoneal CD43−ve B cells. Data were normalized using 18S then expressed relative to FOB. (g) B cell subsets were sorted into splenic 
FOB (CD23hiCD21loCD43−ve), peritoneal cavity B1a (CD19hiCD43+veCD5+ve) and B1b (CD19hiCD43+veCD5−ve) cells. Sorted cells were cultured in the presence of 
apoptotic cells and R848 at varying concentrations. Cells were stained after 72 h for intracellular CD19+ve IL-10. All experiments are representative of three individual 
experiments [except (c,D), where FACs data are representative of 13 individual experiments. Activation marker changes are graphed from pooled data of min six 
individual mice]. Statistical differences were determine by unpaired Student’s t-test *P < 0.05, **P < 0.01, and ***P < 0.001.
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Jurkat ac generation
Treatment with anti-CD95 (1  μg/ml) induced Jurkat cells to 
become apoptotic after 18  h in culture with serum free RPMI 
(supplemented with 2 mM l-glutamine, 100 U/ml penicillin, and 
100 μg/ml streptomycin). At this point 80% were AnV+ve. Cells 
used in phagocytosis or interaction assays were labeled with cell 
tracker green (Molecular Probes) prior to induction of apoptosis.
B cell isolation
Mouse splenocytes were “teased apart” to obtain single cell 
suspensions and depleted of red cells with red cell lysis buffer 
(Sigma-Aldrich, St. Louis, MO, USA). B cells were isolated from 
spleen single cell suspensions or peritoneal lavages using positive 
selection with CD19+ microbeads as per manufacturer’s instruc-
tions (Miltenyi Biotech). Cells were then further sorted by FACS 
as per figure legends.
In Vitro Tlr stimulation assays
1 ×  105 FACS sorted B cells were cultured in complete IMDM 
along with 1  ×  106 apoptotic thymocytes and the relevant 
stimulation. After 72 h, supernatants were removed and cytokine 
levels checked by ELISA (All R&D Duoset ELISA kit except 
IL-35 Biolegend). Cells were stimulated with: TLR7/8 ligand 
R848 [InVivogen (0.1  μg/ml for B  cell stimulation, 0.5  μg/ml 
for macrophage stimulation)], the mouse TLR9 ligand CpGB 
[ODN1826 Eurofins MWG Operon (1  μg/ml)], LPS [Sigma 
(2  μg/ml)], MOG35–55 [Cambridge Research Biochemicals 
(20 μg/ml unless otherwise stated)], or OVA323–339 [Cambridge 
Research Biochemials (2 μg/ml unless otherwise stated)].
In Vivo il-10+ve B cell antibody generation
IL-10-GFP mice were injected IV on D0, D2, and D5 with 
20 × 106 apoptotic thymocytes. On D7 mice were sacrificed and 
blood, peritoneal lavage and spleens harvested. Splenic CD19+ve 
B cells were FACs sorted into IL-10-GFP+ve or −ve fractions, phe-
notyped and cultured for 10 days in the presence of MegaAPRIL 
[Adipogen (200  ng/ml)], CpGB [ODN1826 Eurofins MWG 
Operon (1  μg/ml)], and IL-4 [R&D System (50  ng/ml)], after 
which culture supernatants were checked for IgM and IgG levels 
(Ready-SET-Go ELISA kit eBioScience).
hybridoma generation
Highly purified IL-10-GFP+ve B1a cells, generated in vivo, were 
fused with SP2/0 cells to generate hybridomas. Cells were cul-
tured with peritoneal macrophages for 7 days and supernatants 
screened (see Figures S3C,D in Supplementary Material) prior to 
subcloning. Colonies were selected on their ability to bind to ACs.
immunofluorescence
Apoptotic Jurkats were incubated with 20 μg/ml of IgM derived 
from the hybridoma supernatant followed by anti mouse IgM-
alexa fluor 488 (1:400 dilution. Molecular probes). The plasma 
membrane was stained with Cell Mask Deep Red plasma mem-
brane stain (1:1,000 in PBS) for 10  min at 37°C and following 
fixation with 3.7% formaldehyde the nucleus stained with DAPI. 
Cells, mounted in ProLong® Gold Antifade Mountant were 
visualized on a Leica SP5 confocal microscope.
antigen elisa
EIA/RIA (costar) 96-well plates were coated with 2  μg/ml 
(in 50  μl PBS) antigen overnight then blocked (PBS  +  1% 
BSA) for 1.5 h. Antigens used were malondialdehyde-modified 
low-density lipoprotein (MDA-LDL), oxidized-LDL (Ox-LDL), 
citrullinated fibrinogen (Cambridge Biosciences); DNA, ssDNA, 
thyroglobulin, yeast RNA, alpha Actinin (Sigma); La, Ro, Smith, 
histone (Arotec Diagnostics); rheumatoid factor (Thermofisher 
Scientific), CWPS (Oxford Biosystems), ApoH (R&D Systems), 
PC-BSA (2B Scientific), and AnV (eBiosciences). Serum samples 
were initially diluted at 1:250. For in vitro-generated antibodies, 
supernatants were initially diluted 1:2. For hybridoma-generated 
antibodies, IgM was determined and supernatants were diluted to 
0.5 μg/ml prior to serial dilutions. Secondary antibody (1:1,000 
dilution) were either anti mouse IgM-HRP (Southern Biotech) or 
anti mouse IgG-HRP (Zymed). MRL/lpr mouse serum (diluted 
FigUre 2 | Continued
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1:250) was used as a positive control while IgM derived from 
IL-10–ve clones that did not bind to ACs were used as negative 
controls.
In Vivo antigen challenge experiments
Single cell suspensions of lymph node cells (from OVA Tg mice) 
were prepared and 5 × 106 cells injected along with 20 × 106 ACs 
FigUre 2 | (a) Apoptotic cells were injected IV at the time of OVA-complete Freund’s adjuvant (CFA) antigenic challenge in vivo. Peritoneal CD19+ve cells were 
harvested on D7 and FACS sorted into CD43−ve or CD43+ve, cultured with OVA peptide and OVA-specific T cells and IL-10 measured after 72 h. Representative flow 
plots and pooled data for intracellular IL-10 staining are shown for CD19+ve cells (i) and CD4+ve cells (ii). Secreted IL-10 was measured in the supernatants by ELISA 
(iii). Cell purity and CD19 expression can be found in Figure S2A in Supplementary Material (N = 10 mice). (B) Splenic CD19+ve cells from OVA-CFA challenge 
experiment in (a) were FACS sorted into IgDhi follicular B (FOB) cells and IgDloCD24hiCD43+ve B1a cells. Sorted cells were cultured with OVA peptide and OVA-
specific T cells and IL-10 measured after 72 h. Representative flow plots and pooled data for intracellular IL-10 staining are shown for CD19+ve cells (i) and CD4+ve 
cells (ii). Secreted IL-10 was measured in the supernatants by ELISA (iii). Cell purity and CD19 expression can be found in Figure S2B in Supplementary Material 
(N = 10 mice). (c) wild-type (WT) BALB/c and TIM1−/− BALB/c B cells (IgDloIgMhiCD21hi) were cultured with (black bars) and without (patterned bars) apoptotic cells 
and activated with R848 (i), and OVA plus OVA-specific T cells (ii). IL-10 in the culture supernatants was assessed after 72 h (n = 8). (D) CD19+veIgDloIgMhi B cells 
were FACs sorted from complement receptor 2−/− (CR2−/−) and control C57BL/6 mice. Cells were cultured with (solid black bars) and without (patterned bars) 
apoptotic cells in the presence of R848. IL-10 was measured in the culture supernatants after 72 h. Data are representative of two experiments using 10 mice in 
total. (e) Splenocytes from mice immunized with OVA-CFA and given apoptotic cells were harvested on D7 and re-stimulated with OVA. IL-10 was measured in the 
supernatants after 72 h. WT controls are shown with open circles, complement receptor 2−/− (CR2−/−) mice with filled circles. Data pooled from three individual mice, 
representative of two experiments, five mice total. (F) Spleen and peritoneal cavity CD19+ve B cells were harvested from naive C57BL/6 and CR2−/− mice. Cells were 
stained to determine subsets of splenic (i) MZB (IgDloIgMhiCD43−ve), B1 (IgDloIgMhiCD43+ve) or peritoneal cavity (ii) B1 (CD19+veCD43+ve). WT are shown with open 
circles and CR2−/− with filled circles. N = 6 (spleen) or 5 (peritoneal cavity). (g) Splenic (CD19+IgDloIgMhiCD43+) and peritoneal (CD19hiCD43+) B1 cells were sorted 
and cultured in the presence of R848 and apoptotic cells. IL-10 was measured after 72 h. WT are shown with open bars and CR2−/− shown with filled bars. Data 
representative of n = 3. Statistical differences were determine by unpaired Student’s t-test *P < 0.05, **P < 0.01, and ***P < 0.001.
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(IV). For experiments with C1q−/− mice, C1q−/− thymocytes were 
cultured in serum free X-Vivo 15 media. Mice were immunised 
with 50 μl OVA323–339 peptide (1 mg/ml) emulsified in an equal 
volume of complete Freund’s adjuvant (CFA) sc into each hind 
leg. On D7 splenic single cell suspensions were generated prior to 
restimulation using 1 × 106 splenic cells along with OVA323–339 
peptide at 4, 2, 1, 0.5, and 0 μg/ml. After 72 h, cytokines were 
measured (R&D duoset ELISA).
T cell Proliferation
Splenic cells were labeled with 1 μM CFSE before setting up in 
culture with 2 μg/ml OVA323–339. Cells were harvested every 24 h 
and further stained with CD3 and Ly5.1 (for OTII). The mean 
florescence intensity (MFI) of CFSE for CD3+ve Ly5.1+ve cells was 
measured using flow cytometry.
B cell interaction assays
Purified B  cells were incubated with cell tracker green labeled 
AC-Jurkats in a ratio of 1:5. After 4 or 24 h, cells were stained for 
CD19 and CD43. Interaction was measured using flow cytometry 
by determining the percentage of B cells which were also positive 
for cell tracker green, indicating interaction between the B cell 
and AC.
Preparation of Primary Bone Marrow-
Derived Macrophages (BMDMs)
Bone marrow-derived macrophages were isolated from the 
hind leg bones of C57BL/6 mice and cells cultured in compete 
IMDM + 10% L929-conditioned media (containing M-CSF) for 
7 days in flat bottom plates.
Phagocytosis assay
1 × 106 cell tracker green labeled AC-Jurkats were incubated with 
20 μg/ml of hybridoma derived IgM and cocultured with BMDM 
for 30 m.
Macrophage-B cell cocultures
Peritoneal CD43+veB1a or splenic follicular B (FOB) cells were 
activated with R848 (0.1 μg/ml) for 24 h and then cocultured with 
R848 (0.5 μg/ml) activated BMDM for 18 h. 20 μg/ml anti-IL-10 
or isotype control antibody (Biolegend) was added for length 
of culture. Supernatants were assessed for released cytokines by 
ELISA (R&D duoset) and cells were stained for IC cytokines.
induction and assessment of eae
Experimental autoimmune encephalomyelitis was induced 
as described previously (15). On D3/4 mice were either given 
1 × 105 CD43+ve B1 cells or splenic FOB, that had been previously 
activated with R848 (0.1  μg/ml) for 48  h. Following sacrifice, 
harvested organs were weighed and single cell suspensions from 
the spleen and LN generated. Spinal cords were collagenase/
DNase digested before running over 70/30% Percoll gradient 
to obtain leukocytes. Re-stimulation assays were set up using 
1 × 106 splenic or LN cells or 1 × 105 spinal cord cells along with 
MOG35–55 peptide at 20, 10, 5, 2.5, and 0 μg/ml. After 72  h, 
cytokines were measured (R&D duoset ELISA) and IC staining 
performed.
Bhlhe41 mrna Determination
RNA was extracted from 105 purified cells [TRI® Reagent 
(Ambion)] followed by reverse transcription [High Capacity 
cDNA reverse transcription kit (Applied Biosystems)]. Bhlhe41 
cDNA levels were quantitated by Taqman® Gene Expression 
Assay predesigned primers (Mm00470512_m1) with intra-sam-
ple expression normalized to Eukaryotic 18S rRNA Endogenous 
control (FAM™/MGB probe) and run on an Applied Biosystems 
7900HT Fast-Real Time System using SDS software (v2.4). Data 
were analyzed using the comparative CT method (Δ/ΔCT), 
where fold differences in gene expression between FOB and other 
B cell populations (ΔCT) were normalized to CT values of the 18S 
rRNA reference gene.
statistical analysis
Experimental repeats are given under each experiment and ranged 
from 3 to 12. Data are expressed as mean and SEM. Statistical 
significance between the groups was assessed by GraphPad Prism 
Version 7.0 using the appropriate analysis as stated in the figure 
legends. P-values: *0.01–0.05, **0.001–0.01, and ***<0.001.
FigUre 3 | Continued
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FigUre 3 | Regulatory B cells that recognize apoptotic cells, produce both IL-10 and IgM autoantibodies. (a) Splenic follicular B (FOB) cell (patterned bars), or 
peritoneal cavity B1a cells (solid bars), activated with R848, were cultured with CM-green labeled apoptotic cell (AC) Jurkat cells. (i) B cell–AC interaction was 
assessed by flow cytometry at 4 and 24 h. Representative plots can be found in Figure S3Ai in Supplementary Material. (ii) Cells were also visualized by confocal 
microscopy to show B/AC interaction. IgM+ve B cell (red), AC (green). Scale bar represents 20 μm. Single color controls can be found in Figure S3Aii in 
Supplementary Material. Data representative of two separate experiments. (B) ELISA of serum IgM from mice given AC infusions 7 days earlier. Naive untreated mice 
are shown in the patterned bars and AC-treated mice in the solid bars. Data pooled of five individual mice and from two experiments. (c) IL-10+ve and IL-10−ve 
CD19+ve B cells were isolated from spleens on D7 post-AC injection and cultured with MegaAPRIL, IL-4, and CpG. (i) Supernatants were tested for IgM on Day 10. 
Data are representative of n = 3. (ii) ELISA of secreted IgM from (c) (i). IgM from IL-10−ve cells is shown with patterned bars and IL10+ve cells with solid bars. Data 
representative of n = 3 and pooled from two individual experiments. (D) CD19+ve IL-10+ve B cells were fused with SP0/2 cell line to produce hybridomas as illustrated 
in Figure S3C in Supplementary Material. Clones, which produced antibody that bound apoptotic cells, were further sub-cloned and screened again for apoptotic 
cell binding (Figure S3D in Supplementary Material). Positive binding clones were then checked for IgM to specified autoantigens using an equal concentration of 
IgM per clone tested. Binding from IL-10−ve B cell clones were used as a negative control (shown with dotted line on each graph). No IgG was detected (data now 
shown). Positive control (red line) serum from MRL-lpr/lpr lupus mouse was included. Data are pooled from three individual experiments.
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resUlTs
acBregs are Primarily B1a cells
To identify naturally occurring populations of ACBregs, 
we sorted splenic B  cells into transitional 2 marginal zone 
precursor B  cells (T2-MZP-CD21hiCD24hiCD23hi), FOB  cells 
(CD21loCD24loCD23+ve), and B cells found within the marginal 
zone (CD21hiCD24hiCD23lo) (Figure  1A, i; Figure S1A in 
Supplementary Material). Subsequent stimulation of these B cell 
subsets with the TLR7/8 ligand R848 or the TLR9 ligand CpGB 
in the presence of ACs significantly augmented the level of IL-10 
secretion from CD21hiCD24hiCD23lo splenic B cells (Figure 1A, 
ii–iii, population A3), but barely at all from either T2-MZP B 
(Figure 1A, ii–iii, population A4) or FOB cells (Figure 1A, ii–iii, 
population A1). To further define the surface markers expressed 
by ACBregs, highly pure populations of splenic B  cells were 
also sorted according to their expression of CD21, IgM, and 
IgD (Figure 1B, i; Figure S1B in Supplementary Material). ACs 
induced the highest secretion of IL-10 (but not IL-35), from acti-
vated CD21hiIgMhiIgDlo B cells (Figure 1B, ii–iii, population C4).
To identify in  vivo-derived ACBregs, apoptotic thymocytes 
were administered intravenously to mice and splenic IL-10+ve and 
IL-10−ve B cells harvested 7 days later (Figure S1C in Supplementary 
Material for sort strategy and purity). At this point the percentage 
of IL-10+ve B cells had doubled (Figure 1C, i). Further analysis 
of the surface markers indicated that approximately 80% of the 
splenic IL-10+ve B cells were B1a cells (CD19hiCD43+veCD5+veCD
23lowCD38+veCD25+veCD1d+veIgDlowIgMhi) (Figure 1C, ii; red line 
and Figure S1Ciii–iv in Supplementary Material). In line with 
possible in  vivo activation (see Figure S1Cv in Supplementary 
Material), CD21 expression was reduced following AC infusion 
(30). Compared to IL-10−ve B cells, ACBregs also expressed more 
CD86, Tim1, CD9, CD80, and CD40 (Figure 1C, iii).
To assess the differential responses of activated splenic 
B  cells to ACs, highly purified splenic MZB (CD19+veCD43−ve 
IgDlowIgMhi), B1a (CD19+veCD43+veIgDlowIgMhi), or FOB 
(CD19+veCD43−veIgD+veIgMlo) B cells were cocultured with OVA 
peptide, OVA-specific T  cells, with and without ACs. Cultures 
containing B1a cells generated significantly more IL-10 than 
MZB (Figure 1D). However, MZB were also able to respond to 
ACs and secreted significantly more IL-10 than those cultures 
containing FOBs. This indicates that while splenic B1a B  cells 
make up a major component of ACBregs, activated splenic 
CD43−ve MZB cells can also respond to ACs by secreting IL-10.
Similar results were seen in the peritoneal cavity (PerC). 
Following an injection of ACs the percentage of IL-10+ve B cells 
in the PerC had increased by 50% at day 7 when compared to 
naive mice (Figure  1E, i). Approximately 96% of the IL-10+ve 
B cells were CD43+ve and had the markers of PerC B1a B cells 
(Figure  1E, ii; red line and Figure S1Di–iii in Supplementary 
Material). Again, the expression of CD86, Tim1, CD9, CD80, 
MHCII, and CD40 were also increased compared to IL-10−ve 
B  cells (Figure  1E, iii). As expected, the CD5 staining on the 
B1a B cells was lower than that found on T cells (Figure S1Ei in 
Supplementary Material). However, prior treatment with ACs 
did not alter the percentage of cells that expressed CD43 or CD5 
(Figure S1Eii–iii in Supplementary Material). In keeping with a 
recent report (31), CD43+ve splenic and peritoneal B1a B cells 
preferentially expressed the transcription factor Bhlhe41, when 
compared to splenic FOB or marginal zone B cells and peritoneal 
CD43−ve B cells (Figure 1F). In vitro, the percentage of IL-10+ve 
B1a B  cells is augmented by apoptotic thymocytes, but this 
requires a second signal such as TLR7/8 activation (Figure 1G).
B1a B cells augment T cell il-10 
Production
We next asked if B1a B cells, isolated following an in vivo inflam-
matory immune response, could still induce antigen-specific 
T cells to secrete IL-10. Ovalbumin peptide (OVA323–339)-specific 
D011.10 T cells were transferred into mice that had been given 
an intravenous injection of ACs at the time of OVA323–339 peptide 
(emulsified in CFA) immunization. A week later, PerC B  cells 
were sorted into CD19hiCD43+ve and CD19+veCD43−ve subsets 
(Figure S2A in Supplementary Material). Splenic CD19+ve B cells 
were harvested and sorted into naive CD19+veIgDhi B  cells and 
CD19hiCD43+ve splenic B1a cells (Figure S2B in Supplementary 
Material). These B cell subsets were used as antigen-presenting 
cells (APCs) to stimulate naive OVA323–339-specific T  cells and 
IL-10 production was assessed after 72 h (Figures 2A,B, i,iii). IC 
staining confirmed that the highest percentage of IL-10 produc-
ing cells was still seen among the splenic and PerC CD43+ve B1a 
B cells. These same B1a B cells also induced a significantly higher 
percentage of CD4+ve T cells to produce IL-10 (Figures 2A,B, ii). 
FigUre 4 | Continued
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FigUre 4 | IL-10 from regulatory B cells can inhibit macrophage activation. (a) Supernatants from IL-10+ve and IL-10−ve B cell hybridomas generated in Figure 3D 
were pooled and binding to apoptotic cells tested by microscopy (i and ii). Cell membrane is stained with cell mask plasma membrane dye shown in red, IgM green 
and DAPI blue. Scale bar represents 20 μm. Single color controls can be found in Figure S4 in Supplementary Material. Supernatant was also used in macrophage 
phagocytosis assays (iii). Data representative of n = 3. (B) Splenic follicular B (FOB) cells (CD19+veCD23+veCD21loCD43−ve) or peritoneal cavity B1a cells 
(CD19+veCD43+veCD5+ve) were FACs sorted and activated with R848 for 24 h, prior to coculture for a further 18 h with R848 activated bone marrow-derived 
macrophages (BMDM). Supernatants obtained from cultures of R848 activated B1a cells (B1a sup) was also added to R848 stimulated BMDM. TNFα was 
measured in the supernatants of cocultures (i) and by intracellular staining of F4/80+ve CD19−ve BMDM at end of culture (ii and iii). (c) Surface expression of CD86 
(MFI) on F4/80+ve BMDM at end of culture. (D) IL-10 was measured in the supernatants of cocultures. (e) TNFα (i) and IL-10 (ii) was measured in the supernatants of 
cocultures (BMDM and B1a cells) in the presence of anti-IL-10 antibody or isotype control. Data representative of two experiments with duplicate treatments per 
experiment except (e) where n = 3. Statistical differences were determined by unpaired Student’s t-test *P < 0.05, **P < 0.01, and ***P < 0.001.
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Hence splenic or PerC ACBregs were able to induce antigen-
specific T cells to secrete IL-10, even following a proinflammatory 
in vivo stimulus.
acBregs Do not require Tim1 But are 
augmented in c1q−/− and cr2−/− Mice
T  cell Ig and mucin domain (Tim1) has been reported to 
identify ACBregs and the loss of this molecule has been associ-
ated with impaired IL-10 production and the promotion of 
inflammatory T cell responses (32, 33). To ask if splenic B cells 
required Tim1 expression to induce IL-10 secretion following 
interaction with ACs, IgMhiIgDloCD21hi splenic B  cells from 
WT and Tim1-deficient (Tim1−/−) mice were stimulated with 
the TLR7/8 ligand R848 or used as APCs to stimulate naive 
OVA323–339-specific T cells in vitro. We did not detect any dif-
ference in the ability of TLR or T cell activated Tim1−/− B cells 
to respond to ACs by secreting IL-10 (Figure  2C, i–ii) [on 
both the BALB/c or C57BL/6 background (see Figure S2Di–iv 
in Supplementary Material)]. Nor was there a difference 
in regulatory cell surface markers or their ability to interact 
with ACs (Figures S2E,F in Supplementary Material). Similar 
results were seen when splenic B cells were stimulated with the 
TLR9 ligand CpGB or the TLR4 ligand LPS (Figure S2Gi–ii 
in Supplementary Material). When ACs were given in  vivo 
at the time of OVA323–339/CFA immunization (as described 
for Figure 2A) no differences in IL-10 secretion (Figure S2H 
in Supplementary Material) or T  cell proliferation upon re-
stimulation (Figure S2I in Supplementary Material) was seen; 
leading us to conclude that Tim1 is not required for innate-like 
regulatory B cells to induce regulation.
Mammalian DNA has been shown to bind to CR2/CD21, 
which is most highly expressed by MZB and PerC B1 B  cells 
(34, 35). ACs express DNA containing chromatin complexes on 
their cell surface and altered expression of CR2 is associated with 
SLE in mice (36). In addition, complement proteins, including 
C1q, bind to late ACs and increase their uptake by phagocytes 
(21, 37, 38); the loss of which is believed to contribute to the 
increased risk of SLE (20). Hence complement may also play 
an essential role in regulatory B  cell function. To test this, we 
assessed the cytokine responses of WT or CR2−/− splenic B cells, 
activated with TLR7/8 or TLR9 and cocultured with ACs. To 
avoid bias that may occur with B cell surface markers from these 
knockout mice, we assessed CD19+IgDloIgMhi B cells. In contrast 
to TIM1−/− B  cells, TLR stimulated CD19+IgDloIgMhi CR2−/− 
B cells secreted significantly more IL-10, both with or without 
added ACs (Figure 2D; Figure S2K in Supplementary Material). 
Similar results were seen following the in  vivo immunization 
with OVA323–339 peptide in CFA, OVA323–339-specific T cells and 
an infusion of ACs. Re-stimulation of splenocytes from these 
immunized mice a week later also generated significantly more 
IL-10 than WT controls (Figure 2E). The increase in IL-10 secre-
tion may have resulted from the significantly higher percentage 
of splenic CD43+ve B1a cells found among the CD19+IgDloIgMhi 
B cells (Figure 2F, i). The percentage of peritoneal B1 cells was also 
significantly increased (Figure 2F, ii). When equivalent numbers 
of splenic (CD19+IgDloIgMhiCD43+) or PerC (CD19hiCD43+) 
B1 cells were isolated from CR2−/− mice or WT controls and 
activated with TLR7/8 (R848) and ACs, similar amounts of 
IL-10 were generated (Figure  2G). Comparable results were 
seen with splenic CD21hiIgDloIgMhi B  cells from C1q−/− mice 
(Figures S2L–N in Supplementary Material). This indicates that 
while ACBreg function is not affected by the absence of TIM1, 
it is augmented in both C1q- and CR2-deficient mice, likely as a 
result of the higher percentage of splenic and peritoneal B1a cells, 
able to respond to ACs.
regulatory B1a cells are specific for ac 
expressed neoantigens
Regulatory B cell function depends on the activation of endoso-
mally located TLRs (15). Peritoneal B1 B cells have been reported 
to internalize beads and bacteria (39), but we could not detect 
whole ACs or apoptotic bodies within them (data not shown). 
However, in comparison to follicular cells, peritoneal B1a B cells 
made prolonged contact with ACs at both 4 and 24 h following 
coculture; with significantly more B1a cells still firmly bound to 
ACs (Figure  3A, i–ii; Figure S3A in Supplementary Material). 
These stable interactions may allow the recognition of AC 
expressed neoantigens via the B cell receptor (40), which we and 
others have previously reported to be required for regulatory 
B cell function (14, 41, 42).
Apoptotic cells express a range of self-antigens on their 
cell surface, including DNA, the proteins Ro and La, and 
the phospholipid phosphatidylserine, all of which are potent 
autoantigens in SLE and Sjogren’s syndrome (17, 19). Following 
PCD membrane LDLs also undergo peroxidation, resulting in 
the formation of neoepitopes including MDA-LDL, Ox-LDL, 
and phosphorylcholine (PC) (22). In contrast to the PerC, the 
spleen is a major site of antibody production by B1a B cells (28) 
and following an infusion of ACs, a rise in the titer of IgM (but 
not IgG) with specificities typical of NAbs was observed in the 
FigUre 5 | B1a cells protect mice from experimental autoimmune encephalomyelitis (EAE) by reducing cell inflammatory cell influx into the spinal cord.  
(a) Mean clinical score of mice treated with either splenic follicular B (FOB) cells (CD19+veCD23+veCD21loCD43−ve) (open circles) or peritoneal cavity B1a cells 
(CD19+veCD43+veCD5+ve) (filled circles) that had been treated with the TLR7/8 ligand R848 for 48 h in vitro. Data representative of six individual mice. (B) Number of 
cells per mg of spinal cord tissue. (c) CD4+ve T cells and CD19+ve B cells within the spinal cord. Representative plots can be found in (i) and pooled data from three 
individual mice graphed (ii). (D) Cells were restimulated with 20 μg/ml MOG for 72 h before measuring, (i) IL-17, (ii) IFN-γ, and (iii) GM-CSF in the supernatants. Data 
from FOB-treated mice is shown with patterned bars, and B1a-treated mice shown with solid bars. Cultures were also IC stained for cytokines. Representative plots 
from spinal cord CD4+ve cells are shown in (iv) and data pooled from three individual mice graphed for IL-17 (v), IFN-γ (vi), and GMCSF (vii). Statistical differences 
were determine by unpaired Student’s t-test *P < 0.05, **P < 0.01, and ***P < 0.001.
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serum (Figure 3B) (22). To ask whether IL-10+ve splenic B cells 
were the source of these antibodies, IL-10+ve and IL-10−ve splenic 
B cells were sorted seven days after the administration of ACs 
(as shown in Figure S1Ci–ii in Supplementary Material). These 
cells were cultured in vitro with a proliferation inducing ligand 
(APRIL), IL-4, and CpGB to stimulate antibody secretion. After 
10 days, supernatants were harvested and tested for the specific-
ity of secreted immunoglobulin. Only IL-10+ve splenic B  cells 
secreted significant quantities of IgM (Figure 3C, i) but not IgG 
(data not shown). The antibodies secreted into the supernatants 
were of similar specificities to those antibodies seen in the 
serum of mice injected with ACs (Figure  3C, ii); confirming 
that IL-10+ve regulatory B cells respond to AC expressed neo-
antigens by secreting NAbs. To further assess the specificity of 
these regulatory cells, IL-10+ve and IL-10−ve splenic B cells were 
sorted from mice that had been given an infusion of ACs 7 days 
earlier. As noted before, IL-10+ve B cells had the markers of B1a 
B  cells (Figure S3B in Supplementary Material). B  cells were 
then fused with the SP2/0 cell line to form hybridomas (as illus-
trated in Figures S3C,D in Supplementary Material). Individual 
clones were tested for reactivity to a variety of epitopes found on 
ACs and within the NAb repertoire. Again, only IgM secreted 
by the hybridomas originating from the IL-10+ve (but not 
IL-10−ve) splenic B1a cells, showed cross-reactivity with a range 
of epitopes expressed on ACs, particularly MDA-LDL, Ox-LDL, 
and the autoantigens Ro, La, histones, and Smith (Sm) protein 
(Figure 3D). Hence, ACBregs that respond to ACs are B1a cells 
that secrete both IL-10 and IgM with specificities that resemble 
NAbs.
acBregs inhibit Macrophage 
Proinflammatory Function
Natural antibodies augment the clearance of ACs (43) and 
IgM secreted by ACBregs preferentially bound to ACs, while 
the antibodies derived from IL-10−ve splenic B  cells did not 
(Figure 4A, i–ii; Figures S4A,B in Supplementary Material). The 
phagocytosis of ACs by BMDM, that had bound ACBreg derived 
IgM, was also significantly increased (Figure 4A, iii), as expected 
(44). BMDMs are particularly sensitive to the effects of IL-10, 
which is largely responsible for the anti-inflammatory response, 
acting via the IL-10 receptor and increasing signaling through the 
JAK1/STAT3 cascade (45). In contrast, TLR7/8 stimulation with 
R848 induces BMDMs to secrete TNFα. We noted that, in dis-
tinction to FOB cells, the coculture of B1a B cells with BMDMs, 
where both cell types had been activated with R848, resulted 
in a significant decrease in the amount of TNFα secreted into 
the culture medium (Figure 4B, i), as well as the percentage of 
macrophages (F4/80+CD19−) positive for IC TNFα (Figure 4B, 
ii–iii). Supernatants transferred from R848 activated B1a B cells 
to similarly activated macrophages also diminished TNFα pro-
duction (Figure 4B, i–iii), as well as the activation marker CD86 
(Figure 4C). IL-10 secreted by activated B1a cells (Figure 4D) 
was required to prevent TNFα secretion, as evidenced by the loss 
of macrophage TNFα suppression in the presence of anti-IL-10 
antibodies (Figure 4E, i–ii).
activated B1a B cells suppress 
autoimmunity
The neuroinflammatory disease model EAE is driven by both 
activated, antigen-specific T  cells and macrophages. We next 
asked if activated B1a could limit auto-immune mediated inflam-
mation. Mice were immunized with MOG peptide emulsified 
in CFA (MOG/CFA) to induce EAE. PerC B1a cells and splenic 
FOB cells were stimulated with the TLR7/8 ligand R848 for 48 h 
in vitro and either 105 B1a cells or 105 FOB cells were injected 
intravenously 3–4 days following immunization with MOG/CFA. 
Despite activating the B1a cells with a proinflammatory stimulus 
(via TLR7/8 with R848), clinical disease severity was significantly 
reduced (Figure  5A). On day 20 the spinal cords of control 
FOB  cell-treated mice (FOB) also contained a greater number 
of total cells compared to those given B1a cells (Figure  5B), 
though cell numbers in the spleen and draining lymph nodes 
were unchanged (data not shown). The spinal cords were further 
analyzed for CD4+ve and CD19+ve cells. Compared to B1a-treated 
mice, the percentage of CD4+ve T cells in the spinal cords of mice 
given control FOB  cells was more than six times higher, while 
CD19+ve B cell infiltration was approximately halved in B1a-treated 
mice (Figure 5C, i–ii). Lymphocytes from the spleen, draining 
lymph nodes and spinal cord were re-stimulated with MOG 
peptide for 72 h and the cytokines IL-17, IFN-γ, and GM-CSF 
quantified by ELISA. In keeping with the reduced inflammation 
seen clinically, B1a-treated mice generated significantly less pro-
inflammatory cytokines than control FOB cell-treated mice in all 
organs tested, but particularly the spinal cords (Figure 5D, i–iii). 
IC cytokine staining confirmed that a source of these cytokines 
was the CD4+ve T cell, which again showed a significantly lower 
production of IL-17, IFN-γ, and GM-CSF in B1a-treated mice 
(Figure 5D, iv–vii). This confirms that activated B1a B cells are 
able to suppress autoimmune mediated inflammation when 
administered after the initiation of EAE.
DiscUssiOn
This report pinpoints self-reactive, CD43+ve B1a cells, which 
express the transcription factor Bhlhe41, found in the spleen 
and PerC, as a major responder to ACs. Of the remaining 20% 
of splenic CD43−ve B cells, that similarly responded to ACs, it is 
likely that many of these reside within the MZB cell population. 
Dying cells are a potent source of expressed neoantigens (17, 46), 
which are recognized by ACBregs via their BCR and TLR recep-
tors, leading to the secretion of both IL-10 and NAbs (14, 15). 
We show that this both accelerates the clearance of ACs by 
macrophages and simultaneously reduces macrophage proin-
flammatory responses. Furthermore, ACBregs induce antigen-
specific T  cells to secrete IL-10 and suppress the induction of 
autoimmune CNS inflammation. Hence AC-specific B1a B cells 
fulfill two important homeostatic functions; they ensure, via Nab 
secretion, the rapid disposal of apoptotic corpses and, via IL-10 
secretion, they prevent inflammatory autoimmune responses. 
Activated macrophages orchestrate much of the tissue injury 
seen in autoimmune diseases including rheumatoid arthritis, 
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multiple sclerosis, psoriatic arthritis and inflammatory bowel 
disease (47). IL-10 is a key regulator of activated macrophages 
(48) and as such, activated IL-10 secreting ACBregs are likely to 
play a physiologically relevant role, both in preventing a break 
in self-tolerance and containing ongoing autoimmune responses.
In contrast, we found that T2 marginal zone precursor B cells 
(T2-MZB) secreted much less IL-10 in response to activation 
by TLR ligands and coculture with ACs. This confirms that 
while T2-MZB precursor B  cells regulate particular immune 
responses, they do not play a clear role in mediating tolerogenic 
responses to apoptotic self (11, 49). Tedder et al. have previously 
described a population of IL-10 secreting “B10” cells, which are 
enriched in the expression of CD1d and CD5 (8, 9). They are 
functionally defined in mice and humans by their ability to 
secrete IL-10 following 5 h of ex vivo stimulation with lipopoly-
saccharide (LPS), phorbol ester, and ionomycin (PMA/Iono). 
The term B10 usefully includes all B cells that have the capacity 
to secrete IL-10 following this stimulus. However, it neces-
sarily encompasses B  cell subtypes with differing origins and 
functional attributes and does not enable one to determine the 
particular characteristics of regulatory B cells that are concerned 
with self-tolerance. In addition, TLR activated B cells increase 
their expression of CD1d (see Figure S1Cvi in Supplementary 
Material), which further complicates drawing firm conclusions 
about subset origin.
Early studies confirmed that B1a B cells were self-reactive as 
well as being a major source of IL-10 (3, 24, 25, 28). They constitu-
tively express STAT3 which binds to the IL-10 promoter, further 
enhancing the generation of IL-10 (26, 50). Once activated, they 
migrate away from the coelomic cavities into the spleen, bone 
marrow, and other lymphoid organs, where they secrete immune 
modulatory IL-10 and NAbs (51, 52); so maintaining a tolero-
genic environment toward AC expressed neoantigens. B1a devel-
opment and NAb secretion does not require foreign antigenic 
stimulation, which occurs under gnotobiotic conditions (53). 
Indeed, it has long been suspected that ACs play an important 
role in their development and these data further support a central 
relationship between dying cells and B1a cell function.
Apoptotic cell responsive regulatory B  cells generate poly-
clonal IgM that binds particularly well to AC expressed neoan-
tigens including MDA-LDL, Ox-LDL, PC, Ro, La, histones, and 
Smith antigen; which accelerates their clearance. The prototypic 
NAb T15, identified over 40 years ago, arises within a week of 
birth in the absence of pathogens, and also binds to PC that is 
expressed on pneumococci (54, 55). T15-NAbs similarly bind to 
oxidatively modified LDL, reducing the inflammation associated 
with atherosclerosis (56) and arthritis (57, 58) via a direct effect 
on dendritic cells and macrophage function.
Phosphatidylserine which is exposed on the surface of ACs, is 
recognized by members of the TIM domain family (that includes 
TIM1, TIM3, and TIM4) (59). Considering previous reports of a 
requirement for TIM1 expression by regulatory B cells (32, 33, 60), 
we were surprised to find that TIM1-deficient B  cells on both 
the BALB/c and the C57BL/6 background responded normally 
to ACs, both in vitro and in vivo, by secreting IL-10. These differ-
ences could have arisen from alternative gene knockout strate-
gies, because in TIM1-deficient mice where immune regulation 
is altered, only the mucin domain of TIM1 has been deleted. 
In contrast, we analyzed TIM-1-deficient mice that lacked the 
full-length molecule. Complement deficiency is also believed to 
influence the predisposition to autoimmunity because of an ina-
bility to coat ACs with C1q or the later complement components. 
Such opsonization is required for the efficient clearance of ACs 
by phagocytes (61). Again, we were intrigued to find that, rather 
than a loss of regulatory B cell function, the absence of either C1q 
or CR1/CR2 led to enhanced IL-10 secretion. This was explained 
by the increased frequency of splenic and PerC B1a B cells in both 
knockout phenotypes and confirms that C1q or CR1/CR2 are not 
needed for B1a B cells to secrete IL-10 in response to ACs or TLR 
ligand stimulation. In relation to autoimmunity, B1a B cells in the 
NZB/W F1 lupus model class switch to IgG and accumulate in the 
spleen and target organs (62). In addition, B1a B cells are crucial 
in the NOD mouse model of diabetes (63). We would speculate 
that tissue-specific signals and/or unique pathogen derived sig-
nals combine to determine whether the response of B1a cells is 
predominantly regulatory (via IL-10/NAbs) or proinflammatory 
(via GM-CSF/NAbs) (27, 29, 64).
In summary then, we have delineated that a major population 
of regulatory B cells that responds to ACs are B1a cells. This popu-
lation of B1a cells functions to optimize the disposal of ACs (via 
Nabs), while inhibiting macrophage proinflammatory responses 
and promoting regulatory T cell responses to self-antigens (via 
IL-10). If an equivalent population of B cells could be harnessed 
in humans, it would provide a valuable means to regulate autoim-
munity and transplant rejection.
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FigUre s1 | (a) Purity checks of populations A1, A3, and A4 used in 
Figure 1a. (B) Purity checks of populations C1, C3, and C4 used in Figure 1B. 
(c) Sorting strategy (i) and purity checks (ii) of splenic IL-10+ve cells which were 
further analyzed in Figure 1c. (iii) Percentage of IL-10+ve splenic CD19+ve B cells 
which express CD43 (as a marker of splenic B1a) is 77.8%. (iv) The average 
mean florescence intensity (MFI) data represented in Figure 1c (ii) are shown 
along with the mean fold difference. (v) Change in CD21 expression postculture 
is shown as a histogram with unstimulated marginal zone B cells shown in black 
and the same cells shown after 72 h R848 culture in red. (vi) Change in CD1d 
expression postculture is shown as a histogram with unstimulated CD19+ve cells 
shown in black and the same cells shown after 72 h R848 culture in red. Isotype 
control is shown in shaded gray. (D) (i) Percentage of IL-10+ve peritoneal cavity 
(PerC) CD19+ve B cells which express CD43 is 96%. (ii) The average MFI data 
represented in Figure 1e, ii, are shown along with the mean fold difference. (iii) 
Representative dot plot of peritoneal CD19+ve B cell used in Figure 1e, ii, 
showing expression of CD5 and IL-10. (e) (i) Level of expression of CD5 in 
peritoneal CD5−ve B cells (black), CD5+ve B cells (red) and T cells (blue). 
Percentage of CD43+ve (ii) or CD5+ve (iii) PerC B cells in Naiïve or apoptotic  
cellAC -treated mice used in Figure 1e and (S1D).
FigUre s2 | (a) Purity checks of peritoneal cavity (PerC) CD43−ve and CD43+ve 
(i) and CD19 expression of sorted populations with CD43−ve in black and CD43+ve 
in red (ii) used in Figure 2a. (B) Gating strategy of populations sorted from 
spleen used in Figure 2B, i. Cells were sorted into IgDhi (D1 70.1% of all B cells) 
follicular B (FOB) cells and IgDlo (D2 21.1% of all B cells). D2 was further sorted 
into CD24hiCD43+ve (D3 30.1% of D2) splenic B1 cells. Purity checks can be seen 
in (ii) and CD19 expression of sorted cells (iii) with FOB shown in black and B1a 
shown in red. (c) Example genotyping of TIM1−/− BALB/c (i) and TIM1−/− 
C57BL/6 (ii) mice used in Figure 2c. Wild-type (WT) mice show a 264-bp band 
whereas TIM1−/− mice show a 383-bp band. (D) WT C57BL/6 and TIM1−/− 
C57BL/6 B cells (IgDloIgMhiCD21hi) were FACS sorted and cultured with (black 
bars) and without (patterned bars) apoptotic cells. Cultures were stimulated with 
R848 (i), CpG (ii), lipopolysaccharide (LPS) (iii), and OVA plus OVA-specific T cells 
(iv) and IL-10 measured after 72 h. Results are pooled from five mice. (e) 
Histogram plots of B cell markers in isolated B cell populations. Isotype control is 
shown in gray, WT BALB/c dotted black line, TIM1−/− BALB/c dashed black line. 
Data representative of n = 4 (using 11 mice total). (F) FACs sorted splenic FOB 
(IgDhiIgMlo), MZB (IgDloIgMhiCD21hi) and CD19+ve peritoneal cavity (PerC) cells 
were cultured for 2 h with apoptotic cells in a 1:5 ratio. WT BALB/c is shown with 
solid bar, TIM1−/− BALB/c with patterned bar. Data representative of two 
experiments (using nine mice total). (g) WT BALB/c and TIM1−/− BALB/c B cells 
(IgDloIgMhiCD21hi) were cultured with (black bars) and without (patterned bars) 
apoptotic cells and activated with CpG-B (i), and LPS (ii). IL-10 in the culture 
supernatants was assessed after 72 h. (n = 8). (h) Apoptotic cells were injected 
at the time of OVA-complete Freund’s adjuvant (CFA) antigenic challenge in vivo 
into WT BALB/c and TIM1−/− BALB/c mice. Spleens were removed on D7 and 
restimulated with OVA peptide. IL-10 was measured in culture supernatants after 
72 h (n = 3). (i) Splenocytes (taken from OVA-CFA antigenic challenged mice that 
had been given apoptotic cells) were labeled with CFSE and restimulated with 
OVA. Proliferation of OVA-specific T cells was measured. CFSE MFI of CD3+ve 
T cells was determined and plotted as a % decrease from Day 1. WT spleen 
open circles, TIM1−/− spleen filled circles. Data representative of two experiments 
with duplicate treatments per experiment. (J) Histogram showing representative 
screening data for CD21−/− mice. Binding of anti CD21 antibody to WT B cells 
can be seen (dashed line) compared to no binding seen with CD21−/− mice (solid 
line). Data representative of n = 6. (K) CD19+veIgDloIgMhi B cells were FACs sorted 
from CR2−/− and control C57BL/6 mice. Cells were cultured with (solid black 
bars) and without (patterned bars) apoptotic cells in the presence of CpG-B. 
IL-10 was measured in the culture supernatants after 72 h. Data are 
representative of two experiments using 10 mice in total. (l) 
CD19+veIgDloIgMhiCD21hi B cells were FACs sorted from C1q−/− and control WT 
C57BL/6 mice. Cells were cultured with (solid black bars) and without (patterned 
bars) apoptotic cells in the presence of R848 (i) or CPG (ii). IL-10 was measured 
in supernatants after 72 h. Representative of n = 4. (M) Splenocytes (from 
OVA-CFA challenged mice given apoptotic cells) were harvested on D7 and 
cultured with OVA. IL-10 (i) and IL-6 (ii) was measured in the supernatants after 
72 h. WT controls are shown in open circles, C1q−/− mice in filled circles. Data 
pooled from three individual mice, representative of three individual experiments 
using eight mice total. (n) Spleen CD19+ve B cells were harvested from naive 
C57BL/6 and C1q−/− mice. Cells were stained to determine proportion of B1 
(IgDloIgMhiCD21hiCD43+ve) B cells. WT are shown with open circles and 
C1q−/− with filled circles. N = 6 mice. Statistical differences were determine by 
unpaired Student’s t-test *P < 0.05, **P < 0.01, and ***P < 0.001.
FigUre s3 | (a) Representative dot plots showing interaction of B cells and 
apoptotic cells (i) showing splenic follicular B cells on left and peritoneal cavity 
B1a cells on right. Upper plots show 4 h culture, lower 24 h culture. Single color 
control images for microscopy staining shown in Figure 3a, ii, can be seen in 
[(a), ii]. Scale bar represents 20 μm. (B) Histogram plots for surface markers of 
IL-10+ve B cells (in red), used to generate hybridomas in Figure 3D, compared to 
IL-10−ve B cells (in black) and isotype control (in shaded gray). (c) Schematic 
representation of hybridoma generating process. (D) Supernatants from 
hybridoma clones (Figure 3D) and subsequent pooled supernatants used in 
Figure 4a were incubated with apoptotic cells. Binding could be seen in IL-10+ve 
sups (dashed line) but not IL-10−ve sups (solid lines) to jurkats (i) and thymocytes 
(ii) but not viable jurkats (iii).
FigUre s4 | (a) Supernatants used in Figure 4a showed no binding to viable 
jurkats. Cell membrane red, IgM green, DAPI blue. Scale bar represents 20 μm. 
(B) Single stained controls for Figure 4a showing single cell mask plasma 
membrane dye in red, IgM staining in green, and DAPI in blue. Scale bar 
represents 60 μm.
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